NERVGEN PHARMA CORP. Increase Decrease In Cash And Cash Equivalents
NERVGEN PHARMA CORP. (NGEN) reported Increase Decrease In Cash And Cash Equivalents of CAD 4.80 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-31.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2026-03-31
| Period end | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|
| 2025-12-31 | 4.80M CAD 40-F · filed 2026-03-31 |
| 2024-12-31 | 5.61M CAD 40-F · filed 2026-03-31 |